canceldeath
Registry update — unassessed

The Effect of Semaglutide in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis

Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.

RCTNotable significance
Reporter brief

What this changes

The finding has not established an approved change to our evidence assessment.

Source date: Sep 4, 2026 · Discovered: Sep 23, 2026 · Assessed: — · Research update

What it does not prove

  • This abstract contains no results, only study design details, so no efficacy claims can be assessed.
  • The study is still ongoing (described prospectively), so outcomes remain unknown.
  • No information is provided on which specific NASH endpoints (fibrosis, inflammation, liver function, or clinical events) will be measured or have been achieved.

Extracted from supplied source material; model confidence is not a measured probability of correctness.

Design
Rct
Sample size
—
Duration
60 months
Population
Subjects with non-cirrhotic non-alcoholic steatohepatitis (NASH). Excludes participants with other chronic liver diseases. Excludes pregnant, breast-feeding, or potentially pregnant women.
Primary outcome
—
Effect size
—
Significance
Not reported
Journal
Novo Nordisk A/S
Published
Sep 4, 2026

Funding: Novo Nordisk A/S (sponsor)

Conflicts: Study is conducted by Novo Nordisk A/S, the manufacturer of semaglutide

Recorded source passages

Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.

Participants will either get semaglutide or a dummy medicine - which treatment participants get is decided by chance.
The study will last for about 5 years.
Women cannot take part in the study if they are pregnant, breast-feeding or plan to become pregnant during the study period.
Participants with other chronic liver diseases cannot take part in this study.

Assessment history

One thread per scientific event, no matter how many outlets covered it.

Sign in to join the discussion.

No comments yet

Be the first to weigh in on this evidence.